Mirror, Mirror on the Wall Who's the Most Ambitious Big Pharma Company of Them All?
Since I don’t have a magic mirror, I can only go on what I read in the Internet. And, it appears that Roche may be the most ambitious pharma company of them all; at least by 2013. According to a post on PharmLive, “Roche’s late-stage pipeline is progressing well with potentially ten regulatory submissions of new molecular entities until the end of 2013.”
So what drugs make up this rather full pipeline?
- T-DM1 (trastuzumab-DM1)-antibody-drug conjugate for Her-2 positive breast cancer
- Pertuzumab/trastuzumab (Herceptin)-monoclonal antibody cocktail to treat Her-2
- positive breast cancer
- MetMab-a unique monovalent monoclonal antibody for non-small cell lung cancer
- GA101/RG7159-the first glycoengineered type II humanized anti-CD20 monoclonal for relapsed/refractory progress non-Hodgkins lymphoma
- RG7204-anti-BRAF protein monoclonal antibody for BRAF-mutation-positive metastatic lung cancer
- RG1678-first-in-class glycine reuptake inhibitor that normalizes glutamate neurotransmission for schizophrenia and other psychiatric indications
- RG1594 (ocrelizumab)-humanized anti-CD20 monoclonal for multiple sclerosis
Not surprisingly, many of these molecules were developed at Genentech, the world’s largest biotechnology company that was purchased by Roche almost two years ago.
Until next time...
Good Luck and Good Job Hunting!!!!
.jpg)
I have heard from many jobseekers, who—despite many years of work experience— are having difficulty finding full time employment. During economic down turns many companies cannot or are reluctant to hire full time employees. However, this doesn’t mean that there is work to be done. Consequently, many firms look for part-time, temporary or contract workers to handle the work that must get done to maintain operations.
